NVAX

NOVAVAX INC

Nasdaq · Biological Products, (No Diagnostic Substances) · Inc. DE · CIK 0001000694
$8.88 -1.66% $1.5B
High Impact Filing (8/10)15 New Institutional Positions11 Institutional Exits
Vol
Market Cap$1.5B
Cap SizeSmall Cap
Analyst ConsensusBuy (67%)
Inst. Holders50 funds
Inst. Value$623.5M
Inst. Activity15 buys / 11 sells
Reddit Sentiment63° Warm
SEC Reports3
Exchange Nasdaq·Sector Biological Products, (No Diagnostic Substances)·Inc. DE·CIK 0001000694·Prev Close $9.03

Recent Activity

May 28, 2026 short_volume
Short Volume: NVAX — 56.8% short (1.9M / 3.4M)
Short: 1,925,087 | Exempt: 5,156 | TRF Vol: 3,386,560 | Short Ratio: 56.8% | Off-exchange volume (da
May 6, 2026 SEC
Novavax reported Q1 2026 total revenue of $140M, down 79% YoY from $667M, which included $603M in non-cash APA close-out
8-K — Impact 4/10
Apr 27, 2026 SEC
Novavax has filed definitive additional proxy materials, indicating an active shareholder vote or corporate action. The
DEFA14A — Impact 2/10
Apr 25, 2026 Insider
Newton Charles W. acquired via exercise 9,520 shares
Director
Apr 14, 2026 Insider
Walker Robert Edward was granted 99,500 shares
EVP, R&D
Apr 14, 2026 Insider
Walker Robert Edward was granted 66,000 shares
EVP, R&D
Feb 26, 2026 SEC
Novavax reported strong financial results for Q4 and full year 2025, with revenue up 67% YoY to $147 million in Q4 and $
8-K — Impact 8/10
Inst.
COATUE MANAGEMENT LLC — NEW
3,836,986 shares ($31.2M)

Price Targets

$14.11 +58.9% upside Strong Buy
Current $8.88 Low $7.00 Median $16.02 High $25.00 9 analysts
$7.00 $25.00

Analyst Ratings

Buy67% buy · 15 analysts
4Strong Buy
6Buy
2Hold
2Sell
1Strong Sell
Recent Analyst Actions
DateFirmActionRating
Jun 11, 2026 BTIG REITERATE Buy → Buy
May 6, 2026 TD Cowen MAINTAIN Hold → Hold
Feb 27, 2026 HC Wainwright & Co. MAINTAIN Buy → Buy
Jan 20, 2026 BTIG REITERATE Buy → Buy

Earnings Estimates

PeriodEPS Est.RangeGrowth#
Current Q $-0.38 $-0.50 — $-0.25 -161% YoY 7
Next Q $-0.02 $-0.44 — $0.53 98% YoY 7
Current FY $-0.47 $-1.38 — $0.52 -118% YoY 9
Next FY $-0.25 $-0.85 — $0.80 46% YoY 9

Latest Reports

NEUTRAL 8-K 4/10
Novavax reported Q1 2026 total revenue of $140M, down 79% YoY from $667M, which included $603M in non-cash APA close-out
May 6, 2026
NEUTRAL DEFA14A 2/10
Novavax has filed definitive additional proxy materials, indicating an active shareholder vote or corporate action. The
Apr 27, 2026

Top Institutional Holders

FundValueMove
BlackRock, Inc.$104.6M—
STATE STREET CORP$73.0MADD
D. E. Shaw &$62.8MADD
VANGUARD PORTFOLIO MANAGEMENT LLC$58.2M—
VANGUARD CAPITAL MANAGEMENT LLC$58.0M—

Recent Insider Trades

DateInsiderTypeValue
Apr 25, 2026Newton CharlesM$0.00
Apr 14, 2026Walker RobertA$0.00
Apr 14, 2026Walker RobertA$0.00
Mar 10, 2026Shiver JohnM$0.00
Mar 7, 2026Kelly JamesF$58.9K

Reddit Sentiment

63°
Warm
Bearish Neutral Bullish
4 mentions 2 bullish 0 bearish
50 institutional holders with $623.5M total value (76,625,748 shares) as of 2026-Q1. Top holders: BlackRock,, STATE, D.. Net buying activity: 15 institutions added/increased vs 11 reduced.

Top Institutional Holders — 2026-Q1

#FundSharesValue% of TrackedLast Move
1BlackRock, Inc.12,844,319$104.6M16.8%—
2STATE STREET CORP8,970,518$73.0M11.7%ADD +32.3%
3D. E. Shaw & Co., Inc.7,709,858$62.8M10.1%ADD +40.2%
4VANGUARD PORTFOLIO MANAGEMENT LLC7,151,625$58.2M9.3%—
5VANGUARD CAPITAL MANAGEMENT LLC7,130,147$58.0M9.3%—
6BANK OF AMERICA CORP /DE/6,637,213$54.0M8.7%DOUBLED +167.3%
7COATUE MANAGEMENT LLC3,836,986$31.2M5.0%NEW
8Allianz Asset Management GmbH1,859,854$15.1M2.4%ADD +64.9%
9SUSQUEHANNA INTERNATIONAL GROUP, LLP1,580,600$12.9M2.1%—
10Point72 Asset Management, L.P.1,518,211$12.4M2.0%DOUBLED +9137.7%
11GOLDMAN SACHS GROUP INC1,409,446$11.5M1.8%—
12CHARLES SCHWAB INVESTMENT MANAGEMENT INC1,373,505$11.2M1.8%—
13BARCLAYS PLC1,191,079$9.7M1.6%—
14MARSHALL WACE, LLP1,166,197$9.5M1.5%ADD +25.5%
15CITADEL ADVISORS LLC1,123,746$9.1M1.5%—
16VANGUARD FIDUCIARY TRUST CO1,107,186$9.0M1.4%—
17SUSQUEHANNA INTERNATIONAL GROUP, LLP847,400$6.9M1.1%—
18SUSQUEHANNA INTERNATIONAL GROUP, LLP834,842$6.8M1.1%—
19TWO SIGMA INVESTMENTS, LP614,799$5.0M0.8%—
20MORGAN STANLEY572,034$4.7M0.7%NEAR_EXIT -84.6%

Recent Position Changes

FundActionPrev SharesCurr SharesChange %ValueQuarter
COATUE MANAGEMENT LLCNEW—3,836,986—$31.2M2026-Q1
Point72 Asset Management, L.P.DOUBLED16,4351,518,211+9137.7%$12.4M2026-Q1
MARSHALL WACE, LLPADD929,6111,166,197+25.5%$9.5M2026-Q1
MORGAN STANLEYNEAR_EXIT3,717,984572,034-84.6%$4.7M2026-Q1
FIRST TRUST ADVISORS LPADD297,319409,328+37.7%$3.3M2026-Q1
GROUP ONE TRADING LLCTRIM474,577342,064-27.9%$2.8M2026-Q1
STATE OF WISCONSIN INVESTMENT BOARDDOUBLED60,406200,216+231.5%$1.6M2026-Q1
ALPS ADVISORS INCADD133,432181,025+35.7%$1.5M2026-Q1
CANADA PENSION PLAN INVESTMENT BOARDTRIM393,700120,000-69.5%$976.8K2026-Q1
BANK OF MONTREAL /CAN/DOUBLED16,437108,725+561.5%$885.0K2026-Q1
STRS OHIOTRIM106,00074,600-29.6%$607.2K2026-Q1
BNP Paribas Asset Management Holding S.A.DOUBLED1,63062,453+3731.5%$508.4K2026-Q1
Brevan Howard Capital Management LPNEAR_EXIT271,09952,639-80.6%$428.5K2026-Q1
Russell Investments Group, Ltd.ADD38,71352,281+35.0%$424.9K2026-Q1
Freestone Grove Partners LPTRIM97,00028,176-71.0%$229.4K2026-Q1
FARALLON CAPITAL MANAGEMENT LLCNEAR_EXIT195,00022,000-88.7%$179.1K2026-Q1
Pictet Asset Management Holding SAADD16,29121,342+31.0%$173.7K2026-Q1
HSBC HOLDINGS PLCTRIM58,78118,628-68.3%$148.6K2026-Q1
VICTORY CAPITAL MANAGEMENT INCTRIM27,25518,138-33.5%$147.6K2026-Q1
DZ BANK AG Deutsche Zentral Genossenschafts Bank, Frankfurt am MainTRIM43,71615,824-63.8%$125.2K2026-Q1
BANCO BILBAO VIZCAYA ARGENTARIA, S.A.TRIM20,04710,531-47.5%$82.8K2026-Q1
Rockefeller Capital Management L.P.ADD3,5555,633+58.5%$45.9K2026-Q1
FEDERATED HERMES, INC.ADD3,0934,753+53.7%$38.7K2026-Q1
NATIONAL BANK OF CANADA /FI/DOUBLED8542,048+139.8%$16.7K2026-Q1
CWM, LLCDOUBLED8591,829+112.9%$14.9K2026-Q1
8 unique insiders with 33 transactions. Net insider value: $0.00 ($0.00 bought, $0.00 sold).

Insider Transactions

DateInsiderTitleTypeSharesPriceValue
Apr 25, 2026Newton Charles W.DirectorEXERCISE9,520——
Apr 14, 2026Walker Robert EdwardEVP, R&DAWARD99,500——
Apr 14, 2026Walker Robert EdwardEVP, R&DAWARD66,000——
Mar 10, 2026Shiver John W.DirectorEXERCISE7,947——
Mar 7, 2026Kelly James PatrickEVP, CFO and TreasurerTAX W/H5,904$9.98$58.9K
Mar 7, 2026Kelly James PatrickEVP, CFO and TreasurerEXERCISE12,223——
Mar 3, 2026Kelly James PatrickEVP, CFO and TreasurerEXERCISE43,167——
Mar 3, 2026O'Hara ElaineEVP, Chief Strategy OfficerEXERCISE56,334——
Mar 3, 2026Casey Mark JEVP, Chief Legal OfficerEXERCISE4,000——
Mar 3, 2026Draghia-Akli RuxandraEVP, Research & DevelopmentD26,667——
Mar 3, 2026Jacobs John CPresident and CEOEXERCISE150,167——
Mar 3, 2026Casey Mark JEVP, Chief Legal OfficerEXERCISE37,500——
Mar 3, 2026Draghia-Akli RuxandraEVP, Research & DevelopmentEXERCISE26,667——
Mar 2, 2026Draghia-Akli RuxandraEVP, Research & DevelopmentAWARD139,500——
Mar 2, 2026Draghia-Akli RuxandraEVP, Research & DevelopmentAWARD93,000——
Mar 2, 2026Draghia-Akli RuxandraEVP, Research & DevelopmentAWARD139,500$9.09$1.3M
Mar 2, 2026Jacobs John CPresident and CEOAWARD367,500——
Mar 2, 2026Jacobs John CPresident and CEOAWARD551,500$9.09$5.0M
Mar 2, 2026Kelly James PatrickEVP, CFO and TreasurerAWARD194,000$9.09$1.8M
Mar 2, 2026O'Hara ElaineEVP, Chief Strategy OfficerAWARD118,000——
Mar 2, 2026O'Hara ElaineEVP, Chief Strategy OfficerAWARD177,500$9.09$1.6M
Mar 2, 2026Casey Mark JEVP, Chief Legal OfficerAWARD101,000——
Mar 2, 2026Casey Mark JEVP, Chief Legal OfficerAWARD152,000$9.09$1.4M
Mar 2, 2026Kelly James PatrickEVP, CFO and TreasurerAWARD129,500——
Mar 2, 2026O'Hara ElaineEVP, Chief Strategy OfficerAWARD177,500——
Mar 2, 2026Jacobs John CPresident and CEOAWARD551,500——
Mar 2, 2026Casey Mark JEVP, Chief Legal OfficerAWARD152,000——
Mar 2, 2026Kelly James PatrickEVP, CFO and TreasurerAWARD194,000——
Mar 1, 2026Casey Mark JEVP, Chief Legal OfficerEXERCISE4,000——
Mar 1, 2026Jacobs John CPresident and CEOEXERCISE83,333——
Mar 1, 2026Kelly James PatrickEVP, CFO and TreasurerEXERCISE58,666——
Mar 1, 2026Kelly James PatrickEVP, CFO and TreasurerD58,666——
Mar 1, 2026O'Hara ElaineEVP, Chief Strategy OfficerEXERCISE19,600——
3 SEC filing reports analyzed. Sentiment: 1 bullish, 0 bearish, 0 mixed, 2 neutral. Avg impact: 4.7/10.
NEUTRAL 8-K 4/10
Novavax reported Q1 2026 total revenue of $140M, down 79% YoY from $667M, which included $603M in no
May 6, 2026
NEUTRAL DEFA14A 2/10
Novavax has filed definitive additional proxy materials, indicating an active shareholder vote or co
Apr 27, 2026
BULLISH 8-K 8/10
Novavax reported strong financial results for Q4 and full year 2025, with revenue up 67% YoY to $147
Feb 26, 2026
∅

No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.

Current analyst consensus: Buy (67% buy). Based on 15 analysts: 4 strong buy, 6 buy, 2 hold, 2 sell, 1 strong sell.

Analyst Price Targets

$14.11 mean target +58.9% upside Strong Buy (2.33)
$7.00 Low $25.00 High
MetricValue
Current Price$8.88
Target Low$7.00
Target Mean$14.11
Target Median$16.02
Target High$25.00
# Analysts9
RecommendationStrong Buy (2.33)

Earnings Estimates & Revisions

PeriodEPS AvgEPS LowEPS HighEPS Growth30d Rev.Up/DownRev. AvgRev. GrowthAnalysts
Current Q
2026-06-30
 $-0.38 $-0.50 $-0.25 -161.0% +0.0% 0↑ 4↓ $0.1B -78.2% 7
Next Q
2026-09-30
 $-0.02 $-0.44 $0.53 98.3% +0.0% 0↑ 3↓ $0.1B 51.1% 7
Current FY
2026-12-31
 $-0.47 $-1.38 $0.52 -118.3% +0.0% 1↑ 6↓ $0.4B -63.5% 9
Next FY
2027-12-31
 $-0.25 $-0.85 $0.80 46.2% +0.0% 4↑ 1↓ $0.3B -37.0% 9

Current Quarter EPS Revision History

TimepointEPS EstimateChange
Current$-0.378
7d ago$-0.378
30d ago$-0.378
60d ago$-0.125-0.253
90d ago$-0.137-0.241
3 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 0 initiations.

Individual Analyst Actions

DateAnalyst FirmActionPrevious RatingNew Rating
Jun 11, 2026 BTIG REITERATE Buy Buy
May 6, 2026 TD Cowen MAINTAIN Hold Hold
Feb 27, 2026 HC Wainwright & Co. MAINTAIN Buy Buy
Jan 20, 2026 BTIG REITERATE Buy Buy

Monthly Consensus History

PeriodStrong BuyBuyHoldSellStrong SellBuy %Distribution
Jun 1, 20264622167%
May 1, 20264622167%
Apr 1, 20264622167%
Mar 1, 20264622167%
Feb 1, 20264622167%
Jan 1, 20264622167%
Strong BuyBuyHoldSellStrong Sell
∅

No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.

63°
Warm
Bearish Neutral Bullish
4 mentions 2 bullish 0 bearish 4 time periods

Reddit Sentiment History

DateMentionsSentimentBullishBearishThreads
May 27, 2026150° Neutral001
May 27, 2026150° Neutral001
May 8, 2026160° Warm101
May 8, 2026160° Warm101

Recent Reddit Threads

r/wallstreetbets Neutral 16d 16h ago
NVAX calls LFG
▲ 1 💬 1 ⚡ 0.5
r/wallstreetbets Bullish 1mo ago
$NVAX calls ftw!
▲ 2 💬 1 ⚡ 0.5
Jun 5, 2026
Clinical Trial
A Study to Evaluate the Safety and Immunogenicity of COVID-19 Vaccine and Influenza Combination Vaccine
Phase Phase 3 — COMPLETED
May 28, 2026
short_volume
Short Volume: NVAX — 56.8% short (1.9M / 3.4M)
Short: 1,925,087 | Exempt: 5,156 | TRF Vol: 3,386,560 | Short Ratio: 56.8% | Off-exchange volume (dark pool + OTC)
May 23, 2026
Clinical Trial
Study to Evaluate Safety and Immunogenicity of COVID-19 Vaccine in Children 6 Months to < 12 Years
Phase Phase 3 — COMPLETED
May 22, 2026
short_volume
Short Volume: NVAX — 57.2% short (1.3M / 2.3M)
Short: 1,307,115 | Exempt: 809 | TRF Vol: 2,285,247 | Short Ratio: 57.2% | Off-exchange volume (dark pool + OTC)
May 11, 2026
short_interest
FTD: NVAX — 60,633 shares ($0.6M) failed to deliver
Settlement: 20260511, Price: $10.11, FTD Value: $612,999.63, NOVAVAX INC COM NEW (DE)
May 8, 2026
short_interest
FTD: NVAX — 736,665 shares ($6.8M) failed to deliver
Settlement: 20260508, Price: $9.23, FTD Value: $6,799,417.95, NOVAVAX INC COM NEW (DE)
May 7, 2026
short_interest
FTD: NVAX — 119,707 shares ($1.1M) failed to deliver
Settlement: 20260507, Price: $9.36, FTD Value: $1,120,457.52, NOVAVAX INC COM NEW (DE)
May 6, 2026
earnings_calendar
NVAX Q1 2026 Earnings Scheduled — 2026-05-06
May 5, 2026
short_volume
Short Volume: NVAX — 63.4% short (0.9M / 1.4M)
Short: 891,231 | Exempt: 661 | TRF Vol: 1,406,623 | Short Ratio: 63.4% | Off-exchange volume (dark pool + OTC)
May 4, 2026
short_volume
Short Volume: NVAX — 56.9% short (0.7M / 1.3M)
Short: 744,064 | Exempt: 18 | TRF Vol: 1,307,456 | Short Ratio: 56.9% | Off-exchange volume (dark pool + OTC)
May 1, 2026
short_interest
FTD: NVAX — 139,587 shares ($1.1M) failed to deliver
Settlement: 20260501, Price: $7.93, FTD Value: $1,106,924.91, NOVAVAX INC COM NEW (DE)
Apr 27, 2026
clinical_trial_readout
T-90d Trial Readout: CIC Vaccine Co-formulated tNIV2 , SARSCoV-2 rS and Matrix-M Adjuvant (Phase 3)
Trial: A Study to Evaluate the Safety and Immunogenicity of COVID-19 Vaccine and Influenza Combination Vaccine Sponsor: Novavax Phase: Phase 3 | Statu
Apr 22, 2026
short_volume
Short Volume: NVAX — 70.6% short (1.3M / 1.9M)
Short: 1,333,843 | Exempt: 573 | TRF Vol: 1,889,474 | Short Ratio: 70.6% | Off-exchange volume (dark pool + OTC)
Apr 17, 2026
Clinical Trial
Study to Compare the Immunogenicity and Safety of 3 Lots of NVX-CoV2373 in Adults
Phase Phase 3 — COMPLETED
Apr 14, 2026
short_interest
FTD: NVAX — 74,688 shares ($0.6M) failed to deliver
Settlement: 20260414, Price: $8.11, FTD Value: $605,719.68, NOVAVAX INC COM NEW (DE)
Apr 10, 2026
short_volume
Short Volume: NVAX — 59.0% short (0.9M / 1.5M)
Short: 858,187 | Exempt: 7,065 | TRF Vol: 1,455,264 | Short Ratio: 59.0% | Off-exchange volume (dark pool + OTC)
Apr 8, 2026
short_volume
Short Volume: NVAX — 60.4% short (0.8M / 1.3M)
Short: 809,027 | Exempt: 0 | TRF Vol: 1,339,990 | Short Ratio: 60.4% | Off-exchange volume (dark pool + OTC)
Feb 26, 2026
earnings_calendar
NVAX Q4 2025 Earnings After Market Close — 2026-02-26